Switch theme
Sign up to access all valuation multiples
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
2014
1.1K+
LTM Revenue $868M
LTM EBITDA $219M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Indivior has a last 12-month revenue (LTM) of $868M and a last 12-month EBITDA of $219M.
In the most recent fiscal year, Indivior achieved revenue of $1.6B and an EBITDA of $113M.
Indivior expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Indivior valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $868M | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $709M | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $219M | XXX | $113M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $215M | XXX | $306M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $151M | XXX | $2.7M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $18.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Indivior's stock price is GBP 9 (or $12).
Indivior has current market cap of GBP 1.1B (or $1.5B), and EV of GBP 1.1B (or $1.5B).
See Indivior trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.5B | XXX | XXX | XXX | XXX | $1.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Indivior has market cap of $1.5B and EV of $1.5B.
Indivior's trades at 1.0x EV/Revenue multiple, and 13.5x EV/EBITDA.
Equity research analysts estimate Indivior's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Indivior has a P/E ratio of 7.5x.
See valuation multiples for Indivior and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBIT | 5.3x | XXX | 5.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 7.5x | XXX | 566.5x | XXX | XXX | XXX |
| EV/FCF | 9.2x | XXX | 226.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIndivior's last 12 month revenue growth is -11%
Indivior's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $0.9M for the same period.
Indivior's rule of 40 is -5% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Indivior's rule of X is -2% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Indivior and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -11% | XXX | -19% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | 73% | XXX | XXX | XXX |
| Rule of 40 | -5% | XXX | -4% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Indivior acquired XXX companies to date.
Last acquisition by Indivior was XXXXXXXX, XXXXX XXXXX XXXXXX . Indivior acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Indivior founded? | Indivior was founded in 2014. |
| Where is Indivior headquartered? | Indivior is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Indivior have? | As of today, Indivior has 1.1K+ employees. |
| Who is the CEO of Indivior? | Indivior's CEO is Mr. Mark Wesley Crossley. |
| Is Indivior publicy listed? | Yes, Indivior is a public company listed on LON. |
| What is the stock symbol of Indivior? | Indivior trades under INDV ticker. |
| When did Indivior go public? | Indivior went public in 2014. |
| Who are competitors of Indivior? | Similar companies to Indivior include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Indivior? | Indivior's current market cap is $1.5B |
| What is the current revenue of Indivior? | Indivior's last 12 months revenue is $868M. |
| What is the current revenue growth of Indivior? | Indivior revenue growth (NTM/LTM) is -11%. |
| What is the current EV/Revenue multiple of Indivior? | Current revenue multiple of Indivior is 1.3x. |
| Is Indivior profitable? | Yes, Indivior is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Indivior? | Indivior's last 12 months EBITDA is $219M. |
| What is Indivior's EBITDA margin? | Indivior's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Indivior? | Current EBITDA multiple of Indivior is 5.2x. |
| What is the current FCF of Indivior? | Indivior's last 12 months FCF is $123M. |
| What is Indivior's FCF margin? | Indivior's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Indivior? | Current FCF multiple of Indivior is 9.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
